RT Journal Article
T1 Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
A1 Hindi, Nadia
A1 Carrasco García, Irene
A1 Sánchez-Camacho, Alberto
A1 Gutierrez, Antonio
A1 Peinado, Javier
A1 Rincón, Inmaculada
A1 Benedetti, Johanna
A1 Sancho, Pilar
A1 Santos, Paloma
A1 Sánchez-Bustos, Paloma
A1 Marcilla, David
A1 Encinas, Victor
A1 Chacon, Sara
A1 Muñoz-Casares, Cristobal
A1 Moura, David
A1 Martin-Broto, Javier
K1 Advanced soft-tissue sarcoma
K1 Trabectedin plus radiotherapy
K1 Palliative therapy
K1 Growth-modulation index
K1 Ifosfamide
K1 Anthracyclines
K1 Dyspnea
K1 Sarcoma
K1 Trabectedina
K1 Radioterapia
K1 Cuidados paliativos
K1 Ifosfamida
K1 Antraciclinas
K1 Disnea
AB Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical trial in this setting. This retrospective series aims to analyze our experience with the same regimen in the real-life setting. We retrospectively reviewed advanced sarcoma patients treated with trabectedin concomitantly with radiotherapy with palliative intent. Growth-modulation index (GMI) was calculated as a surrogate of efficacy. Forty metastatic patients were analyzed. According to RECIST, there was one (2.5%) complete response, 12 (30%) partial responses, 18 (45%) disease stabilizations, and nine (22.5%) progressions. After a median follow-up of 15 months (range 2-38), median progression-free survival (PFS) and overall survival (OS) were 7.5 months (95% CI 2.8-12.2) and 23.5 months (95% CI 1.1-45.8), respectively. Median GMI was 1.42 (range 0.19-23.76), and in 16 (53%) patients, it was >1.33. In patients with GMI >1.33, median OS was significantly longer than in those with GMI 0-1.33 (median OS 52.1 months (95% CI not reached) vs. 8.9 months (95% CI 6.3-11.6), p = 0.028). The combination of trabectedin plus radiotherapy is an active therapeutic option in patients with advanced STS, especially when tumor shrinkage for symptomatic relief is needed.
PB MDPI
YR 2020
FD 2020-12-12
LK http://hdl.handle.net/10668/4448
UL http://hdl.handle.net/10668/4448
LA en
NO Hindi N, Carrasco García I, Sánchez-Camacho A, Gutierrez A, Peinado J, Rincón I, et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers. 2020 Dec 12;12(12):3740
DS RISalud
RD Apr 7, 2025